argenx expands use of Cradle's AI protein-design platform
What's the deal? Cradle, the AI protein-design company, announced on 17 November 2026 that Belgian biotech argenx is expanding its use of Cradle's end-to-end AI platform to more scientists and antibody discovery programmes, following successful results from its initial work. The platform helps researchers design proteins — including antibodies for autoimmune diseases — using AI-guided sequence design combined with laboratory validation.
Why it matters: argenx, best known for its approved autoimmune therapies such as Vyvgart (efgartigimod), is a significant endorsement for Cradle's generative protein engineering approach. The expansion extends a year in which Cradle has signed multiple pharmaceutical partnerships — including with UCB and Hansa Biopharma — underlining the shift of AI protein design from research novelty to a standard tool in antibody discovery.
Read more: PR Newswire, 17 November 2026